Chiral Quest Subsidiary Signs License Agreement with
News Sep 27, 2005
VioQuest's subsidiary Chiral Quest, Inc., (VQPH) signed a licensing agreement granting Merck & Co., Inc. use of its catalysts for the process development and manufacture of single-enantiomer intermediates and active pharmaceutical ingredients.
This agreement provides Merck with access to a broad range of proprietary ligands and catalysts.
Nonalcoholic fatty liver disease produces no noticeable symptoms, but one out of every five people with it will go on to develop a more serious conditions such as nonalcoholic steatohepatosis and cirrhosis. Three new studies investigate how mitochondrial energy production is altered by the progress of fatty liver disease.READ MORE